Trial Profile
Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
- Indications Bone disorders
- Focus Therapeutic Use
- Sponsors NextGen Sciences
- 05 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 05 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.
- 21 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2017, as reported by ClinicalTrials.gov.